about
Left Atrial Enlargement in Young High-Level Endurance Athletes - Another Sign of Athlete's Heart?The association between ace gene variation and aerobic capacity in winter endurance disciplinesThe uefa euro 2012 anti-doping programme - scientific reviewNO ASSOCIATION BETWEEN tHbmass AND POLYMORPHISMS IN THE HBB GENE IN ENDURANCE ATHLETESInsights into Supplements with Tribulus Terrestris used by AthletesOverrepresentation of the COL3A1 AA genotype in Polish skiers with anterior cruciate ligament injury.Total haemoglobin mass, blood volume and morphological indices among athletes from different sport disciplines.Echocardiographic assessment of right ventricle adaptation to endurance training in young rowers - speckle tracking echocardiography.Genes in sport and doping.Total bilirubin in athletes, determination of reference range.Metabolic modulators of the exercise response: doping control analysis of an agonist of the peroxisome proliferator-activated receptor δ (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR).The influence of hypoxic physical activity on cfDNA as a new marker of vascular inflammation.Detection of β-methylphenethylamine, a novel doping substance, by means of UPLC/MS/MS.BUDESONIDE TREATMENT OF PROFESSIONAL ATHLETES AND ANTI-DOPING TESTING--CASE STUDIES.Prevalence and determinants of the early repolarisation pattern in a group of young high endurance rowers.[Possible reasons for the presence of nandrolone metabolites in urine].Pertussis outbreak in Polish shooters with adverse event analysis.Total Hemoglobin Mass, Aerobic Capacity, and HBB Gene in Polish Road Cyclists.Herbal medicine for sports: a review.Upper respiratory tract infection and mucosal immunity in young ice hockey players during the pre-tournament training period.Relationship between ACTN3 R577X polymorphism and maximal power output in elite Polish athletes.Asthma and exercise-induced respiratory disorders in athletes. The position paper of the Polish Society of Allergology and Polish Society of Sports Medicine[Adverse cardiovasular effects of doping in athletes]Screening for benfluorex and its major urinary metabolites in routine doping controlsDetermination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometryIdentification and characterization of urinary prenylamine metabolites by means of liquid chromatography-tandem mass spectrometryOverrepresentation of the ACTN3 XX genotype in elite canoe and kayak paddlersN,N-dimethyl-2-phenylpropan-1-amine - new designer agent found in athlete urine and nutritional supplementThe prevalence of trimetazidine use in athletes in Poland: excretion study after oral drug administrationAnalytical approach for the determination of steroid profile of humans by gas chromatography isotope ratio mass spectrometry aimed at distinguishing between endogenous and exogenous steroidsInterrelationships between changes in erythropoietin, plasma volume, haemoglobin concentration, and total haemoglobin mass in endurance athletesAntibody Response to Trivalent Influenza Vaccine in the Northern and the Southern Hemisphere in Elite AthletesSafety and Impact on Training of the Influenza Vaccines in Elite Athletes Participating in the Rio 2016 OlympicsVitamin B12 Status and Optimal Range for Hemoglobin Formation in Elite AthletesComparison of GC-MS and MEKC methods for caffeine determination in preworkout supplements
P50
Q30364547-5121C873-0A8D-4039-BE1A-806BA12A298CQ33554436-F1715910-F766-4D66-A10D-85130A1EF3A4Q33703035-DA6ACB2E-6F51-44BC-A432-2FB4A13BEAE6Q33703083-FD64EF63-31BD-4648-826E-7E56F0F116C2Q33996656-81F5402F-3CC8-43B6-85D4-2281D77DF3FDQ35661666-C339863A-D7CF-43D9-8895-375265669F49Q37321884-0C05910A-E161-4587-9BBC-C7363FD87919Q37483482-75D06924-A980-437B-BB38-F22508DFE6ACQ37621203-002AD5D5-2A2F-45D7-B98F-72C8D53098EBQ37735064-D7E046E5-9B13-42C3-9880-82B21DFF52F4Q38245364-9BAC4655-4BD9-4961-A548-511D37BB7193Q38703671-2002F0F6-0E5C-4094-B004-142C0F789783Q39756069-F20BA081-4FDE-4FBB-A9ED-D4F9438A32ADQ39893519-04F97CD4-7E7A-42E2-8551-CAFB10445753Q40705917-D03022F2-0C33-4D7B-B7D4-5F4BA57F6FB7Q43194807-78C09695-50CB-46B9-9155-39AFF1287DCFQ47159136-C252B5D3-F1E2-4FA1-B3B3-546C2F04BDFAQ50912036-1534591B-8C3D-43B8-9EA2-1584381E8A73Q51760414-ACE9DB5D-C58E-4958-AB74-B6C5395C073FQ52681452-34416D36-99E4-4BD5-AA80-05EE410E31E0Q54181214-8AEE7B0E-CFA7-4DE8-856B-17EC270C4961Q64115737-2EA3D971-AD4C-4454-93CC-867DFEA3957EQ80676605-050DE1DC-999E-4F03-8C50-8C0D19E39347Q82662644-8FEB5AAF-41E9-4610-8284-3BA8B095645DQ83380057-E7CF7494-BB29-45E6-A5AE-91AE076797DFQ84565174-04B8E2E9-AEA2-4841-BBDA-28BB2245DA1AQ85651953-2193A196-FD45-4CAA-951F-2453433FDF92Q85890383-B341E35B-9A27-493F-8961-136610BE7E2DQ86048683-42511842-772E-4E7E-B550-293F5336FEE3Q86255402-9A0172BD-330E-49B8-9D10-ECFEB7740873Q87999474-9469DA6C-5A06-46A2-ADB9-FDBB46DE3F1DQ89018054-B57FE582-0461-4C6E-B7EA-76BB7BDECEEEQ89593631-D26242A1-EFD3-40CD-818F-F5EAB5E41C81Q91869449-B032B433-7429-4047-987E-BD29AC8C1BA1Q92154004-AD4AB703-3D62-467F-BB4F-FF773F0E4607
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
A Pokrywka
@ast
A Pokrywka
@en
A Pokrywka
@es
A Pokrywka
@nl
type
label
A Pokrywka
@ast
A Pokrywka
@en
A Pokrywka
@es
A Pokrywka
@nl
prefLabel
A Pokrywka
@ast
A Pokrywka
@en
A Pokrywka
@es
A Pokrywka
@nl
P214
P106
P1153
31367647800
P214
P31
P496
0000-0003-4217-7560
P735
P7859
viaf-165131015